Caprion Pharmaceuticals in disease biomarker research collaboration

Published: 14-Aug-2003

Canadian proteomics-based drug discovery company Caprion Pharmaceuticals has entered into a research collaboration with AstraZeneca to identify biomarkers for pain using Caprion's CellCarta proteomics discovery platform.


Canadian proteomics-based drug discovery company Caprion Pharmaceuticals has entered into a research collaboration with AstraZeneca to identify biomarkers for pain using Caprion's CellCarta proteomics discovery platform.

Under the terms of the agreement, Caprion will profile the proteomic changes occurring in plasma resulting from the administration of pharmaceutical compounds in relevant preclinical models.

Caprion's proprietary proteomics technology comprehensively and quantitatively profiles the proteins contained in tissues and blood. Caprion is presently conducting biomarker discovery programs in other indications for several pharmaceutical and biotechnology companies.

'We are very pleased to begin this relationship with Caprion,' said Dr Philippe Walker, vice president, discovery at AstraZeneca r&d Montreal. 'We believe that Caprion's proteomics platform is well suited to identify novel biomarkers that could be used to assess the safety and efficacy of AstraZeneca's experimental compounds.'

You may also like